INCY
Incyte Corporation
118.00$
-3.9%
vs. previous close
Closing price · As of: Nov 5, 2026
Ownership
Ownership Structure
Who owns Incyte Corporation (INCY)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 84.1% of the shares are freely tradable; institutional investors hold 106.6%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
106.6%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
1.9%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
84.1%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
8.4%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
203Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Baker Bros Advisors LP | 15.18 | 30,762,330 | +0.1 | 06/30/2026 |
| BlackRock Inc | 8.90 | 18,032,718 | -5.0 | 06/30/2026 |
| Dodge & Cox | 5.90 | 11,957,326 | -2.4 | 06/30/2026 |
| Vanguard Capital Management, LLC | 5.44 | 11,024,289 | +0.9 | 06/30/2026 |
| State Street Corp | 4.80 | 9,722,336 | +0.8 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 3.84 | 7,791,091 | +0.4 | 06/30/2026 |
| AQR Capital Management LLC | 2.63 | 5,320,901 | -8.4 | 06/30/2026 |
| Geode Capital Management, LLC | 2.34 | 4,750,735 | +1.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Dodge & Cox Stock I | 3.29 | 6,659,728 | -16.3 | 09/30/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.70 | 5,476,725 | +1.4 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Baker Bros. Advisors Lp | Director | 28,206,082 | 3,328,317,676 $ | Sep 30, 2026 | indirect |
| Cagnoni Pablo J | President, Global Head of R&D | 183,200 | 21,617,600 $ | Oct 15, 2026 | direct |
| Meury William | Chief Executive Officer | 183,129 | 21,609,222 $ | Jul 16, 2026 | direct |
| Issa Mohamed Khairie | EVP, Head of U.S. Commercial | 71,797 | 8,472,046 $ | Jul 16, 2026 | direct |
| Mayes Patrick A | EVP & Chief Scientific Officer | 61,441 | 7,250,038 $ | Aug 5, 2026 | direct |
| Heeson Lee | EVP, Head of Incyte Intl | 37,578 | 4,434,204 $ | Oct 1, 2026 | direct |
| Stein Steven H | CMO & Head of Late-Stage Dev. | 30,916 | 3,648,088 $ | Jul 16, 2026 | direct |
| Clancy Paul J | Director | 25,838 | 3,048,884 $ | Sep 30, 2026 | direct |
| Harrigan Edmund | Director | 23,225 | 2,740,550 $ | Sep 30, 2026 | direct |
| Tray Thomas | Principal Accounting Officer | 21,699 | 2,560,482 $ | Jul 16, 2026 | direct |
| Hoffman Richard A. | EVP & General Counsel | 16,861 | 1,989,598 $ | Jul 16, 2026 | direct |
| Gardner David H | EVP, Chief Strategy Officer | 15,904 | 1,876,672 $ | Sep 22, 2026 | direct |
| Basi Ramitpal K | EVP, Human Resources | 10,993 | 1,297,174 $ | Aug 25, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | 2,642 | 112.71 | 297,780 |
| Oct 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Other | 925 | 64.25 | 59,431 |
| Oct 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Other | 455 | 61.18 | 27,837 |
| Oct 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Other | 423 | 61.76 | 26,124 |
| Oct 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Other | 839 | 71.93 | 60,349 |
| Oct 1, 2026 | Heeson Lee | EVP, Head of Incyte Intl | Other | 463 | 117.14 | 54,236 |
| Sep 30, 2026 | Clancy Paul J | Director | Other | 203 | 121.35 | 24,634 |
| Sep 30, 2026 | Baker Bros. Advisors Lp | Director | Other | 322 | 0.00 | – |
| Sep 30, 2026 | Harrigan Edmund | Director | Other | 206 | 121.35 | 24,998 |
| Sep 22, 2026 | Gardner David H | EVP, Chief Strategy Officer | Other | 920 | 126.93 | 116,776 |
| Sep 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | 13,985 | 120.49 | 1,685,053 |
| Sep 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | 9,233 | 120.50 | 1,112,577 |
| Sep 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Other | 9,233 | 71.93 | 664,130 |
| Sep 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Other | 6,477 | 64.25 | 416,147 |
| Sep 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Other | 4,551 | 61.18 | 278,430 |
| Sep 15, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Other | 2,957 | 61.76 | 182,624 |
| Aug 25, 2026 | Basi Ramitpal K | EVP, Human Resources | Other | 504 | 129.72 | 65,379 |
| Aug 19, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | 10,801 | 125.56 | 1,356,174 |
| Aug 12, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | 10,803 | 120.04 | 1,296,792 |
| Aug 5, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 2,207 | 123.99 | 273,646 |
| Aug 5, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 2,207 | 106.47 | 234,979 |
| Aug 5, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | 10,640 | 122.69 | 1,305,422 |
| Aug 3, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 6,055 | 120.43 | 729,204 |
| Aug 3, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 6,055 | 105.43 | 638,379 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 2,293 | 119.41 | 273,807 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 326 | 121.69 | 39,671 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 85 | 122.19 | 10,386 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 1,642 | 119.38 | 196,022 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 1,643 | 119.51 | 196,355 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 2,864 | 119.40 | 341,962 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 4,695 | 119.39 | 560,536 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 6,171 | 119.43 | 737,003 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 2,187 | 119.47 | 261,281 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 5,332 | 119.42 | 636,747 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | 14,661 | 119.46 | 1,751,403 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 326 | 105.43 | 34,370 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 85 | 106.47 | 9,050 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 2,293 | 90.56 | 207,654 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 1,642 | 85.01 | 139,586 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 3,023 | 83.20 | 251,514 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 1,643 | 80.50 | 132,262 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 2,864 | 77.67 | 222,447 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 2,623 | 83.58 | 219,230 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 9,459 | 72.27 | 683,602 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 2,072 | 71.93 | 149,039 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 3,148 | 68.62 | 216,016 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 2,709 | 61.76 | 167,308 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 2,284 | 64.25 | 146,747 |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | 2,918 | 61.18 | 178,523 |
| Jul 31, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | 15,888 | 119.70 | 1,901,794 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.